Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review

Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review

Post-transplant lymphoproliferative disease (PTLD) often exhibits poor prognosis and high mortality, and there are no uniform guidelines for the treatment of this disease. Anti-CD19 chimeric antigen receptor (CAR) T cells show significant efficacy in treatment of relapse/refractory diffuse large B-c...

Full description

Bibliographic Details
Main Authors: Gang Feng, Qing Li, Haibo Zhu, Yanyu Jiang, Jijun Yuan, Yingxin Fu, Qi Deng
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
post-transplant lymphoproliferative disease
diffuse large B-cell lymphoma
programmed cell death 1
chimeric antigen receptor
T cells
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.726134/full

Similar Items

Similar Items